| Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis (NCT03897075) | Sun Pharmaceutical Industries Limited | 2021-05-13 |
| Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (NCT04286607) | Arcutis Biotherapeutics, Inc. | 2020-02-12 |
| Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test (NCT04221906) | Boston Pharmaceuticals | 2020-01-06 |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (NCT04211363) | Arcutis Biotherapeutics, Inc. | 2019-12-20 |
| Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (NCT04211389) | Arcutis Biotherapeutics, Inc. | 2019-12-17 |
| Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (NCT03982394) | AbbVie | 2019-07-01 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT03598790) | UCB Biopharma SRL | 2018-09-05 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT03536884) | UCB Biopharma SRL | 2018-06-13 |
| A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT03410992) | UCB Biopharma SRL | 2018-02-05 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT03412747) | UCB Biopharma SRL | 2018-01-26 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis (NCT03230292) | UCB Biopharma SRL | 2017-07-03 |
| A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis (NCT03025542) | UCB Biopharma SRL | 2016-12-27 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis (NCT03010527) | UCB Biopharma SRL | 2016-12-14 |
| Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis (NCT02969018) | Pfizer | 2016-12-01 |
| A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis (NCT02852967) | Kadmon Corporation, LLC | 2016-09-14 |
| Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (NCT02905006) | UCB Biopharma S.P.R.L. | 2016-08-01 |
| Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (NCT02690701) | Novartis Pharmaceuticals | 2016-02-10 |
| Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis (NCT02581345) | Momenta Pharmaceuticals, Inc. | 2015-09-01 |
| The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis (NCT02570750) | Pfizer | 2015-05-07 |
| Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy (NCT01872546) | Poitiers University Hospital | 2013-01-01 |
| Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (NCT01358578) | Novartis Pharmaceuticals | 2011-06-01 |
| Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy (NCT01200264) | Duke University | 2010-09-01 |
| Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis (NCT00805480) | Novartis Pharmaceuticals | 2008-12-01 |
| Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris (NCT00844363) | Rockefeller University | 2008-11-01 |
| Chronic Plaque Psoriasis (Ps) Registry (NCT00799877) | AbbVie | 2008-09-26 |
| Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis (NCT00770965) | Novartis Pharmaceuticals | 2008-09-10 |
| Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis (NCT00707070) | Universita di Verona | 2008-09-01 |
| Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT00795353) | Astellas Pharma Inc | 2008-07-01 |
| TRUST Study: Raptiva ® in Hand & Foot Psoriasis (NCT00739882) | Merck KGaA, Darmstadt, Germany | 2008-04-01 |
| Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy (NCT00953329) | John Murray | 2008-02-01 |
| ChangE From Any Systemic psoriasiS therapY to Raptiva (NCT00697593) | Merck KGaA, Darmstadt, Germany | 2008-01-01 |
| Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (NCT00574249) | Abbott | 2007-11-01 |
| Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis (NCT00539929) | Eisai Inc. | 2007-09-01 |
| Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis (NCT00493324) | Astellas Pharma Inc | 2007-07-01 |
| A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545 (NCT00472758) | MedImmune LLC | 2007-02-01 |
| LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis (NCT00705900) | NeoStrata Company, Inc. | 2007-01-01 |
| A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis (NCT00419666) | Galderma R&D | 2006-08-01 |
| Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis (NCT00438360) | Novartis Pharmaceuticals | 2006-05-01 |
| Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy (NCT00245765) | UCB Pharma | 2005-10-01 |
| Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients (NCT00422617) | Uni-Pharma | 2005-01-01 |
| Safety and Tolerability of Repeat Courses of IM Alefacept (NCT00794807) | Charite University, Berlin, Germany | 2004-02-01 |
| A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate (NCT00673556) | Astellas Pharma Inc | 2003-10-01 |
| A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis (NCT00674063) | Astellas Pharma Inc | 2003-07-01 |
| Safety and Tolerability of Repeat Courses of IM Alefacept (NCT00233662) | Biogen | 2002-12-01 |
| Topical Vitamin B12 in Chronic Plaque Psoriasis (NCT00350116) | Ruhr University of Bochum | 2001-01-01 |